Lehne's Pharmacotherapeutics for

Advanced Practice Providers (eBook

PDF)
Visit to download the full and correct content document:
https://ebooksecure.com/download/lehnes-pharmacotherapeutics-for-advanced-practi
ce-providers-ebook-pdf/
 Development of New Psychotherapeutic Drugs

Approaching the Study of Central Nervous System Drugs

Chapter 17 Drugs for Parkinson Disease

Pathophysiology That Underlies Motor Symptoms

Overview of Motor Symptom Management

Pharmacology of the Drugs Used for Motor Symptoms

Prescribing and Monitoring Considerations

Chapter 18 Drugs for Alzheimer Disease

Pathophysiology

Risk Factors and Symptoms

Drugs for Cognitive Impairment

Drugs for Neuropsychiatric Symptoms

Can We Prevent Alzheimer Disease or Delay Cognitive Decline?

Chapter 19 Drugs for Epilepsy

Seizure Generation

Types of Seizures

How Antiepileptic Drugs Work

Basic Therapeutic Considerations

Classification of Antiepileptic Drugs

Traditional Antiepileptic Drugs

Newer Antiepileptic Drugs

Prescribing and Monitoring Considerations

Chapter 20 Drugs for Muscle Spasm and Spasticity

 Drug Therapy of Muscle Spasm: Centrally Acting Muscle Relaxants

Drugs for Spasticity

Prescribing and Monitoring Considerations for Drugs Used to Treat Muscle Spasm: Centrally
Acting Skeletal Muscle Relaxants

Unit VI Drugs for Pain

Chapter 21 Local Anesthetics

Basic Pharmacology of the Local Anesthetics

Properties of Individual Local Anesthetics

Clinical Use of Local Anesthetics

Chapter 22 Opioid Analgesics, Opioid Antagonists, and Nonopioid Centrally

Acting Analgesics
Opioid Analgesics

Basic Pharmacology of the Opioids

Prescribing Opioids for Chronic, Noncancer Pain

Clinical Use of Opioids

Opioid Antagonists

Nonopioid Centrally Acting Analgesic—Tramadol

Chapter 23 Drugs for Headache

Migraine Headache

Cluster Headaches

Tension-Type Headache

Medication Overuse Headache

Unit VII Psychotherapeutic Drugs

Chapter 24 Antipsychotic Agents and Their Use in Schizophrenia

 Schizophrenia: Clinical Presentation and Etiology

First-Generation (Conventional) Antipsychotics

Second-Generation (Atypical) Antipsychotics

Depot Antipsychotic Preparations

Management of Schizophrenia

Chapter 25 Antidepressants
Major Depression: Clinical Features, Pathogenesis, and Treatment Overview

Drugs Used for Depression

Peripartum Depression

Somatic (Nondrug) Therapies for Depression

Chapter 26 Drugs for Bipolar Disorder

Characteristics of Bipolar Disorder

Treatment of Bipolar Disorder

Mood-Stabilizing Drugs

Antipsychotic Drugs

Chapter 27 Sedative-Hypnotic Drugs

Benzodiazepines

Benzodiazepine-Like Drugs

Ramelteon: A Melatonin Agonist

Barbiturates

Management of Insomnia

Other Hypnotics

Chapter 28 Management of Anxiety Disorders

 Generalized Anxiety Disorder

Panic Disorder

Obsessive-Compulsive Disorder

Social Anxiety Disorder

Posttraumatic Stress Disorder

Chapter 29 Central Nervous System Stimulants and Attention-

Deficit/Hyperactivity Disorder
Central Nervous System Stimulants

Attention-Deficit/Hyperactivity Disorder

Unit VIII Drug Abuse

Chapter 30 Drug Abuse I

Definitions

Diagnostic Criteria Regarding Drugs of Abuse

Factors That Contribute to Drug Abuse

Neurobiology of Addiction

Principles of Addiction Treatment

The Controlled Substances Act

Chapter 31 Drug Abuse II

Basic Pharmacology of Alcohol

Alcohol Use Disorder

Drugs for Alcohol Use Disorder

Chapter 32 Drug Abuse III

Basic Pharmacology of Nicotine
 Pharmacologic Aids to Smoking Cessation

Chapter 33 Drug Abuse IV

Heroin, Oxycodone, and Other Opioids

General Central Nervous System Depressants

Psychostimulants

Marijuana and Related Preparations

Psychedelics

Dextromethorphan

3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy)

Inhalants

Anabolic Steroids

Unit IX Drugs that Affect the Heart, Blood Vessels, Blood, and
Blood Volume

Chapter 34 Review of Hemodynamics

Overview of the Circulatory System

Regulation of Cardiac Output

Regulation of Arterial Pressure

Chapter 35 Diuretics
Review of Renal Anatomy and Physiology

Introduction to Diuretics

Loop Diuretics

Thiazides and Related Diuretics

Potassium-Sparing Diuretics
Chapter 36 Drugs Acting on the Renin-Angiotensin-Aldosterone System
Physiology of the Renin-Angiotensin-Aldosterone System

Angiotensin-Converting Enzyme Inhibitors

Angiotensin II Receptor Blockers

Aliskiren, a Direct Renin Inhibitor

Aldosterone Antagonists

Chapter 37 Calcium Channel Blockers

Calcium Channels: Physiologic Functions and Consequences of Blockade

Calcium Channel Blockers: Classification and Sites of Action

Verapamil and Diltiazem: Agents That Act on Vascular Smooth Muscle and the Heart

Dihydropyridines: Agents That Act Mainly on Vascular Smooth Muscle

Chapter 38 Vasodilators
Basic Concepts in Vasodilator Pharmacology

Pharmacology of Individual Vasodilators

Chapter 39 Drugs for Hypertension

Basic Considerations in Hypertension

Management of Chronic Hypertension

Drugs for Hypertensive Disorders of Pregnancy

Chapter 40 Drugs for Heart Failure

Pathophysiology of Heart Failure

Overview of Drugs Used to Treat Heart Failure

Digoxin, a Cardiac Glycoside

Management of Heart Failure

Chapter 41 Antidysrhythmic Drugs
Introduction to Cardiac Electrophysiology, Dysrhythmias, and the Antidysrhythmic Drugs

Pharmacology of the Antidysrhythmic Drugs

Chapter 42 Prophylaxis of Atherosclerotic Cardiovascular Disease

Cholesterol

Plasma Lipoproteins

Role of Low-Density Lipoprotein Cholesterol in Atherosclerosis

2013 American College of Cardiology/American Heart Association Guideline on the

Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk

Drugs and Other Products Used to Improve Plasma Lipid Levels

Monoclonal Antibodies (Proprotein Convertase Subtilisin/Kexin Type 9 [PCSK9] Inhibitors)

Chapter 43 Drugs for Angina Pectoris

Determinants of Cardiac Oxygen Demand and Oxygen Supply

Angina Pectoris: Pathophysiology and Treatment Strategy

Organic Nitrates

Beta Blockers

Calcium Channel Blockers

Ranolazine

Treatment Measures

Chapter 44 Anticoagulant and Antiplatelet Drugs

Coagulation: Physiology and Pathophysiology

Overview of Drugs for Thromboembolic Disorders

Anticoagulants

Antiplatelet Drugs
Chapter 45 Drugs for Deficiency Anemias
Red Blood Cell Development

Iron Deficiency

Vitamin B12 Deficiency

Folic Acid Deficiency

Unit X Drugs for Endocrine Disorders

Chapter 46 Drugs for Diabetes Mellitus

Diabetes Mellitus: Basic Considerations

Insulin

Noninsulin Medications for the Treatment of Diabetes

Glucagon for Treatment of Severe Hypoglycemia

Chapter 47 Drugs for Thyroid Disorders

Thyroid Physiology

Thyroid Function Tests

Thyroid Pathophysiology

Thyroid Hormone Preparations for Hypothyroidism

Drugs for Hyperthyroidism

Unit XI Women's Health

Chapter 48 Estrogens and Progestins

The Menstrual Cycle

Estrogens

Selective Estrogen Receptor Modulators

Progestins

Menopausal Hormone Therapy

 Prescribing and Monitoring Considerations

Chapter 49 Birth Control

Effectiveness of Birth Control Methods

Selecting a Birth Control Method

Oral Contraceptives

Combination Contraceptives With Novel Delivery Systems

Long-Acting Contraceptives

Spermicides

Emergency Contraception

Drugs for Medical Abortion

Unit XII Men's Health

Chapter 50 Androgens
Testosterone

Clinical Pharmacology of the Androgens

Androgen (Anabolic Steroid) Abuse by Athletes

Prescribing and Monitoring Considerations

Chapter 51 Drugs for Erectile Dysfunction and Benign Prostatic Hyperplasia

Erectile Dysfunction

Benign Prostatic Hyperplasia

Unit XIII Antiinflammatory, Antiallergic, and Immunologic

Drugs

Chapter 52 Review of the Immune System

Introduction to the Immune System
 Antibody-Mediated (Humoral) Immunity

Cell-Mediated Immunity

Chapter 53 Childhood Immunization

General Considerations

Target Diseases

Specific Vaccines and Toxoids

Chapter 54 Antihistamines
Histamine

The Two Types of Antihistamines: Histamine-1 Antagonists and Histamine-2 Antagonists

Chapter 55 Cyclooxygenase Inhibitors

Mechanism of Action

Classification of Cyclooxygenase Inhibitors

First-Generation Nonsteroidal Antiinflammatory Drugs

Second-Generation Nonsteroidal Antiinflammatory Drugs (Cyclooxygenase-2 Inhibitors,

Coxibs)

Acetaminophen

American Heart Association (AHA) Statement on Cyclooxygenase Inhibitors in Chronic Pain

Chapter 56 Glucocorticoids in Nonendocrine Disorders

Review of Glucocorticoid Physiology

Pharmacology of the Glucocorticoids

Prescribing and Monitoring Considerations

Unit XIV Drugs for Bone and Joint Disorders

Chapter 57 Drug Therapy of Rheumatoid Arthritis

 Pathophysiology of Rheumatoid Arthritis

Overview of Therapy

Nonsteroidal Antiinflammatory Drugs

Glucocorticoids

Nonbiologic (Traditional) Disease-Antimodifying Rheumatic Drugs

Biologic Disease-Modifying Antirheumatic Drugs

Prescribing and Monitoring Considerations for Tumor Necrosis Factor Antagonists

Chapter 58 Drug Therapy of Gout

Pathophysiology of Gout

Overview of Drug Therapy

Drugs for Acute Gouty Arthritis

Drugs for Hyperuricemia (Urate-Lowering Therapy)

Pharmacologic Management of Gout

Chapter 59 Drugs Affecting Calcium Levels and Bone Mineralization

Calcium Physiology

Calcium-Related Pathophysiology

Drugs for Disorders Involving Calcium and Bone Mineralization

Osteoporosis

Prescribing and Monitoring Considerations

Unit XV Respiratory Tract Drugs

Chapter 60 Drugs for Asthma and Chronic Obstructive Pulmonary Disease

Basic Considerations

Antiinflammatory Drugs

Bronchodilators
 Glucocorticoid/Long-Acting Beta2 Agonist Combinations

Beta2-Adrenergic Agonist/Anticholinergic Combinations

Management of Asthma

Management of Chronic Obstructive Pulmonary Disease

Prescribing and Monitoring Considerations

Chapter 61 Drugs for Allergic Rhinitis, Cough, and Colds

Drugs for Allergic Rhinitis

Drugs for Cough

Cold Remedies: Combination Preparations

Unit XVI Gastrointestinal Drugs

Chapter 62 Drugs for Peptic Ulcer Disease

Pathogenesis of Peptic Ulcers

Overview of Treatment

Antibacterial Drugs

Histamine-2 Receptor Antagonists

Proton Pump Inhibitors

Other Antiulcer Drugs

Chapter 63 Laxatives
General Considerations

Basic Pharmacology of Laxatives

Laxative Abuse

Chapter 64 Other Gastrointestinal Drugs

Antiemetics
 Drugs for Motion Sickness

Antidiarrheal Agents

Drugs for Irritable Bowel Syndrome

Drugs for Inflammatory Bowel Disease

Prokinetic Agents

Pancreatic Enzymes

Anorectal Preparations

Unit XVII Nutrition and Complementary Therapies

Chapter 65 Vitamins
Basic Considerations

Fat-Soluble Vitamins

Water-Soluble Vitamins

Chapter 66 Drugs for Weight Loss

Assessment of Weight-Related Health Risk

Overview of Obesity Treatment

Weight-Loss Drugs

A Note Regarding Drugs for Weight Loss

Chapter 67 Complementary and Alternative Therapy

Regulation of Dietary Supplements

Private Quality Certification Programs

Standardization of Herbal Products

Adverse Interactions With Conventional Drugs

Some Commonly Used Dietary Supplements

Harmful Supplements to Avoid

Unit XVIII Therapy of Infectious and Parasitic Diseases

Chapter 68 Basic Principles of Antimicrobial Therapy

Selective Toxicity

Classification of Antimicrobial Drugs

Acquired Resistance to Antimicrobial Drugs

Selection of Antibiotics

Host Factors That Modify Drug Choice, Route of Administration, or Dosage

Dosage and Duration of Treatment

Therapy With Antibiotic Combinations

Prophylactic Use of Antimicrobial Drugs

Misuses of Antimicrobial Drugs

Monitoring Antimicrobial Therapy

Chapter 69 Drugs That Weaken the Bacterial Cell Wall I

Introduction to the Penicillins

Properties of Individual Penicillins

Chapter 70 Drugs That Weaken the Bacterial Cell Wall II

Cephalosporins

Carbapenems

Other Inhibitors of Cell Wall Synthesis

Chapter 71 Bacteriostatic Inhibitors of Protein Synthesis

Tetracyclines

Macrolides

Other Bacteriostatic Inhibitors of Protein Synthesis

Chapter 72 Aminoglycosides
Basic Pharmacology of the Aminoglycosides

Properties of Individual Aminoglycosides

Chapter 73 Sulfonamides and Trimethoprim

Sulfonamides

Trimethoprim

Trimethoprim/Sulfamethoxazole

Prescribing and Monitoring Considerations for Sulfonamides

Prescribing and Monitoring Considerations for Trimethoprim

Chapter 74 Drug Therapy of Urinary Tract Infections

Organisms That Cause Urinary Tract Infections

Specific Urinary Tract Infections and Their Treatment

Urinary Tract Antiseptics

Chapter 75 Antimycobacterial Agents

Drugs for Tuberculosis

Drugs for Mycobacterium Avium Complex Infection

Prescribing and Monitoring Considerations

Chapter 76 Miscellaneous Antibacterial Drugs

Fluoroquinolones

Additional Antibacterial Drugs

Chapter 77 Antifungal Agents

Drugs for Systemic Mycoses
 Drugs for Superficial Mycoses

Chapter 78 Antiviral Agents I

Drugs for Infection With Herpes Simplex Viruses and Varicella-Zoster Virus

Drugs for Cytomegalovirus Infection

Drugs for Hepatitis

Drugs for Influenza

Prescribing and Monitoring Considerations

Chapter 79 Antiviral Agents II

Pathophysiology

Drug Interactions

Classification of Antiretroviral Drugs

Management of HIV Infection

Preventing HIV Infection With Drugs

HIV Vaccines

Keeping Current

Prescribing and Monitoring Considerations

Chapter 80 Drug Therapy of Sexually Transmitted Diseases

Chlamydia Trachomatis Infections

Gonococcal Infections

Nongonococcal Urethritis

Pelvic Inflammatory Disease

Acute Epididymitis

Syphilis

Bacterial Vaginosis
 Trichomoniasis

Chancroid

Herpes Simplex Virus Infections

Proctitis

Venereal Warts

Chapter 81 Anthelmintics
Classification of Parasitic Worms

Helminthic Infestations

Drugs of Choice for Helminthiasis

Unit XIX Drug Therapy for Patients with Cancer

Chapter 82 Anti-Cancer Drugs for the Nonspecialist

Basic Principals of Cancer Chemotherapy

Cytotoxic Agents

Hormonal Agents, Targeted Drugs, and Other Noncytotoxic Anticancer Drugs

Chapter 83 Pain Management in Patients With Cancer

Pathophysiology of Pain

Management Strategy

Assessment and Ongoing Evaluation

Drug Therapy

Nondrug Therapy

Pain Management in Special Populations

Patient Education

The Joint Commission Pain Management Standards

Unit XX Drugs for Eyes, Ears, and Skin

Chapter 84 Drugs for the Eye
Drugs for Glaucoma

Prescribing and Monitoring Considerations for Glaucoma

Drugs for Allergic Conjunctivitis

Prescribing and Monitoring Considerations

Additional Ophthalmic Drugs

Chapter 85 Drugs for the Skin

Anatomy of the Skin

Topical Drug Formulations

Acne

Sunscreens

Drugs for Atopic Dermatitis (Eczema)

Agents Used to Remove Warts

Drugs for Nonsurgical Cosmetic Procedures

Antiperspirants and Deodorants

Drugs for Seborrheic Dermatitis and Dandruff

Drugs for Hair Loss

Eflornithine for Unwanted Facial Hair

Drugs for Impetigo

Local Anesthetics

Chapter 86 Drugs for the Ear

Anatomy of the Ear

Otitis Media and Its Management

Otitis Externa and Its Management

Prescribing and Monitoring Considerations

Another random document with
no related content on Scribd:
 — Je ne suis pas un enfant, dit papa. Ce n’est pas toi qui te
seras renseigné, ce sera moi… Et d’ailleurs, je te garantis qu’ils n’en
sauront rien. Dis-moi seulement le nom…
— La maison Gaudron, de Caen. Elle a plus de cinquante ans
d’existence.
— C’est déjà une recommandation, dit papa… Voyons… il est
sept heures. Je saurai dans une demi-heure tout ce que j’ai besoin
de savoir. A condition, toutefois, que ces demoiselles du téléphone
veuillent bien y mettre de la complaisance…
— Louise, dit-il à la femme de chambre, demandez-moi
Gutenberg 22.64… Arthur, dit-il à Robert, est encore à son bureau.
Sa maison de banque est en relations avec tout ce qu’il y a
d’intéressant en Normandie.
— Papa est bien d’avis que je ne dois pas faire attendre mon
patron ?… J’ai un poste important dans la maison. Et j’ai dit que je
ne serais absent que deux jours…
— Ah non, dit maman, tu arrives ! Tu vas bien rester une semaine
avec nous. Tu n’as pas bonne mine, tu sais, mon garçon…
— Si on l’attend là-bas, dit papa, il ne faut pas plaisanter.
— D’ailleurs, je reviendrai dans très peu de jours. Caen n’est pas
au bout du monde.
Robert pensait : C’est vrai qu’il ne me sera pas impossible de
revenir de temps en temps passer quelques heures avec eux.
Papa fut appelé au téléphone… Il revint quelques minutes après.
— … Oui, la maison est sérieuse. Pas de premier ordre : on ne
dit cela que de trois ou quatre grandes banques. Mais enfin c’est
assez bon… on peut même dire : bon…
— Tu me conseilles toujours, papa, de partir demain ?
— C’est ridicule, dit maman.
— Il ne faut pas mécontenter son patron, dit papa.
— Alors, dit Robert, je prendrai le train de Cherbourg, qui est, je
crois, à 1 h. 30.
 — Je reviendrai déjeuner avec vous, dit papa.
— C’est décidément plus sage de s’en aller, dit encore Robert…
Il était soulevé de bonheur. Il fut d’une gaieté folle pendant tout le
dîner.
On déjeuna le lendemain avant midi. Papa partit ensuite avec
Robert. Il le quitta à la gare Saint-Lazare, car on l’attendait au
bureau. Et le train de la ligne de Cherbourg ne partait qu’une demi-
heure après.
Robert était installé dans son compartiment quand il aperçut tout
à coup, courant sur le quai, sa sœur Jenny… Elle tenait à la main un
télégramme…
— Voici une dépêche qui vient d’arriver pour toi ! dit Jenny tout
essoufflée. Nous avons pris sur nous, maman et moi, de l’ouvrir, et
je crois que nous avons bien fait. Je me suis procuré une auto et je
te réponds qu’elle a rudement marché pour venir directement à la
gare.
La dépêche disait :

Sommes obligés venir Paris. Vous attendons sans faute

Majestic.

Gaudron.

— … Maman s’est rappelé que Gaudron, c’était le nom du

monsieur avec qui tu travaillais. J’ai bien fait de te l’apporter, n’est-ce
pas ?
— Tu es un ange, dit Robert à Jenny, qui ne se lassait pas de
recevoir des félicitations pour son initiative…
Puis il se hâta de reprendre sa valise et de descendre de ce
train, qui s’en alla tout de même à Lisieux, à Caen et à Cherbourg,
en emmenant des infortunés qui ne connaissaient pas Fabienne,
mais qui ignoraient leur malheur.
Robert avait quitté Jenny sur le seuil de la gare, après avoir
échangé de vagues propos de prochaine « revoyure », s’il restait à
Paris. « Mais il ne le croyait pas… » se hâta-t-il de dire, et il pensait
au contraire que son patron et lui repartiraient le soir même pour
Caen.

— Monsieur Gaudron ? demanda Robert au portier de l’hôtel

Majestic.
— Ah ! monsieur Gaudron ? Oui… Il est arrivé de ce matin.
(Ernest était un habitué de l’hôtel.) Mais si je crois bien l’avoir vu
sortir tout à l’heure… C’est possible que madame soit là.
— Peut-elle me recevoir ?
Un coup de téléphone… Robert était ému beaucoup plus encore
qu’à la première entrée de Fabienne dans sa vie…
— Oui, monsieur, dit le portier…
Montée dans l’ascenseur, en compagnie d’un préposé au « lift »,
bien indifférent et bien insouciant sous sa haute casquette…
— Le 214, dit-il, c’est au bout du couloir.
Fabienne attendait, toute sévère et rigide. Robert lui donna force
explications mal ordonnées, répétant énergiquement cette
affirmation qu’il était dans le train de Caen quand la dépêche lui était
parvenue, que, par conséquent, il avait déjà renoncé, de son propre
mouvement, à ce projet de prolonger son séjour…
Le jugement d’acquittement ne fut pas rendu tout de suite. Il ne
faut pas croire que la justice suprême de l’Aimée aille aussi vite que
cela… Et même ce ne furent pas du tout les raisons et les
arguments du défenseur qui fléchirent le tribunal : le tribunal
pardonna simplement quand il en eut assez de bouder, et quand ce
fut son bon plaisir de pardonner.
Ils se regardaient maintenant avec attendrissement…
— Ernest ne va pas rentrer tout de suite ? demanda-t-il au bout
d’un instant.
Sans s’apercevoir du caractère tendancieux de la question, elle
alla jeter un coup d’œil dans la chambre à côté…
 — Il a emporté son pardessus d’auto. C’est donc qu’il est allé à
Versailles, où il avait besoin de voir quelqu’un…
— Chérie ! implora Robert…
— Oh ! non, dit-elle, vous ne voudriez pas !
— Comment ? Je ne voudrais pas ?
— Non, non, cent fois non ! Nous allons aller nous promener tous
les deux. Ça m’amusera beaucoup d’être dans les rues de Paris
avec vous.
— Nous sortirons tout à l’heure. Mais tu vas m’embrasser. Tu
comprends… Je veux avoir l’esprit libre : si nous sortons tout de
suite, je ne serai pas à la conversation. Je t’écouterai parler avec
ravissement, sans entendre un mot de ce que tu dis. Et je ne
réponds pas, aussitôt la nuit tombée, de ma tenue dans les taxis.
Tout cela était assez difficilement réfutable, surtout pour une
personne qui n’apporte plus une grande énergie à la réfutation. Il la
prit dans ses bras. Elle avait dit cent fois non, et n’eut pas à dire une
seule fois oui.
Un moment après, il fallut retaper le lit, et lui donner un aspect
convenable.
— Quoique, dit Fabienne, je puisse très bien m’y être étendue
après le déjeuner pour me reposer. Nous sommes partis ce matin, à
cinq heures.
Il s’assit sur un fauteuil pour la regarder s’habiller. Ah ! quelle
adorable femme !
Chez ses parents, il avait retrouvé, c’était entendu, le chez-lui de
son enfance. Mais son chez-lui de maintenant, c’était partout où était
Fabienne. Et décidément tous les meubles de cette chambre d’hôtel
étaient aussi sympathiques que le buffet de la salle à manger…
Avec Fabienne, nul besoin d’appeler des souvenirs à la
rescousse. Une joie vivante, actuelle, nouvelle, naissait
constamment de sa présence.
Il se leva, s’approcha d’elle et la prit tendrement dans ses bras.
 — Petite Fabienne, tu es ma raison de vivre…
— C’est entendu. Mais nous allons sortir. Maintenant, tu es d’une
ardeur tout de même un peu moins vive que tout à l’heure. La
promenade sera charmante, car, comme tu dis, tu seras à la
conversation. Si nous ne sortons pas tout de suite, tu feras encore
des bêtises. Et, après cela, qu’arrivera-t-il ? C’est que tu seras
endormi et plus du tout à la conversation… Dépêchons-nous donc,
mon chéri : il faut que nous soyons rentrés à six heures. Ernest a
l’intention de nous emmener faire un bon dîner.
— Ernest… dit Robert. Je suis assez content de le revoir…
— Pas tant que lui de te revoir toi. Il trouvait le temps très long, tu
sais, après toi. Je ne sais pas s’il ne nous manquait pas un peu…
— Peut-être, dit Robert.
Il ajouta :
— Ah ! comme je suis content d’être ici !
— C’est que tu y tenais, dit-elle, à voir tes parents.
— C’est vrai, et j’ai eu un grand plaisir à les retrouver. Mais tu ne
peux t’imaginer ce que ce petit retour nécessaire a été une bonne
expérience pour moi ! Je te dis toute la vérité de mon cœur. J’ai été
heureux de les retrouver. J’ai même senti pour eux un amour que je
n’avais jamais éprouvé. C’était un amour conscient, au lieu de
l’amour filial inconscient de mon enfance. Et voilà pourquoi, vois-tu,
cela ne pouvait pas durer…
… Ces douces joies familiales, conclut-il, ont besoin d’être
inconscientes pour être longtemps supportées…

FIN

E. GREVIN. — IMPRIMERIE DE LAGNY

*** END OF THE PROJECT GUTENBERG EBOOK L'ENFANT
PRODIGUE DU VÉSINET : ROMAN ***

Updated editions will replace the previous one—the old editions

will be renamed.

Creating the works from print editions not protected by U.S.

copyright law means that no one owns a United States copyright
in these works, so the Foundation (and you!) can copy and
distribute it in the United States without permission and without
paying copyright royalties. Special rules, set forth in the General
Terms of Use part of this license, apply to copying and
distributing Project Gutenberg™ electronic works to protect the
PROJECT GUTENBERG™ concept and trademark. Project
Gutenberg is a registered trademark, and may not be used if
you charge for an eBook, except by following the terms of the
trademark license, including paying royalties for use of the
Project Gutenberg trademark. If you do not charge anything for
copies of this eBook, complying with the trademark license is
very easy. You may use this eBook for nearly any purpose such
as creation of derivative works, reports, performances and
research. Project Gutenberg eBooks may be modified and
printed and given away—you may do practically ANYTHING in
the United States with eBooks not protected by U.S. copyright
law. Redistribution is subject to the trademark license, especially
commercial redistribution.

START: FULL LICENSE

THE FULL PROJECT GUTENBERG LICENSE
 PLEASE READ THIS BEFORE YOU DISTRIBUTE OR USE THIS WORK

To protect the Project Gutenberg™ mission of promoting the

free distribution of electronic works, by using or distributing this
work (or any other work associated in any way with the phrase
“Project Gutenberg”), you agree to comply with all the terms of
the Full Project Gutenberg™ License available with this file or
online at www.gutenberg.org/license.

Section 1. General Terms of Use and

Redistributing Project Gutenberg™
electronic works
1.A. By reading or using any part of this Project Gutenberg™
electronic work, you indicate that you have read, understand,
agree to and accept all the terms of this license and intellectual
property (trademark/copyright) agreement. If you do not agree to
abide by all the terms of this agreement, you must cease using
and return or destroy all copies of Project Gutenberg™
electronic works in your possession. If you paid a fee for
obtaining a copy of or access to a Project Gutenberg™
electronic work and you do not agree to be bound by the terms
of this agreement, you may obtain a refund from the person or
entity to whom you paid the fee as set forth in paragraph 1.E.8.

1.B. “Project Gutenberg” is a registered trademark. It may only

be used on or associated in any way with an electronic work by
people who agree to be bound by the terms of this agreement.
There are a few things that you can do with most Project
Gutenberg™ electronic works even without complying with the
full terms of this agreement. See paragraph 1.C below. There
are a lot of things you can do with Project Gutenberg™
electronic works if you follow the terms of this agreement and
help preserve free future access to Project Gutenberg™
electronic works. See paragraph 1.E below.
1.C. The Project Gutenberg Literary Archive Foundation (“the
Foundation” or PGLAF), owns a compilation copyright in the
collection of Project Gutenberg™ electronic works. Nearly all the
individual works in the collection are in the public domain in the
United States. If an individual work is unprotected by copyright
law in the United States and you are located in the United
States, we do not claim a right to prevent you from copying,
distributing, performing, displaying or creating derivative works
based on the work as long as all references to Project
Gutenberg are removed. Of course, we hope that you will
support the Project Gutenberg™ mission of promoting free
access to electronic works by freely sharing Project
Gutenberg™ works in compliance with the terms of this
agreement for keeping the Project Gutenberg™ name
associated with the work. You can easily comply with the terms
of this agreement by keeping this work in the same format with
its attached full Project Gutenberg™ License when you share it
without charge with others.

1.D. The copyright laws of the place where you are located also
govern what you can do with this work. Copyright laws in most
countries are in a constant state of change. If you are outside
the United States, check the laws of your country in addition to
the terms of this agreement before downloading, copying,
displaying, performing, distributing or creating derivative works
based on this work or any other Project Gutenberg™ work. The
Foundation makes no representations concerning the copyright
status of any work in any country other than the United States.

1.E. Unless you have removed all references to Project

Gutenberg:

1.E.1. The following sentence, with active links to, or other

immediate access to, the full Project Gutenberg™ License must
appear prominently whenever any copy of a Project
Gutenberg™ work (any work on which the phrase “Project
Gutenberg” appears, or with which the phrase “Project
Gutenberg” is associated) is accessed, displayed, performed,
viewed, copied or distributed:

This eBook is for the use of anyone anywhere in the United

States and most other parts of the world at no cost and with
almost no restrictions whatsoever. You may copy it, give it
away or re-use it under the terms of the Project Gutenberg
License included with this eBook or online at
www.gutenberg.org. If you are not located in the United
States, you will have to check the laws of the country where
you are located before using this eBook.

1.E.2. If an individual Project Gutenberg™ electronic work is

derived from texts not protected by U.S. copyright law (does not
contain a notice indicating that it is posted with permission of the
copyright holder), the work can be copied and distributed to
anyone in the United States without paying any fees or charges.
If you are redistributing or providing access to a work with the
phrase “Project Gutenberg” associated with or appearing on the
work, you must comply either with the requirements of
paragraphs 1.E.1 through 1.E.7 or obtain permission for the use
of the work and the Project Gutenberg™ trademark as set forth
in paragraphs 1.E.8 or 1.E.9.

1.E.3. If an individual Project Gutenberg™ electronic work is

posted with the permission of the copyright holder, your use and
distribution must comply with both paragraphs 1.E.1 through
1.E.7 and any additional terms imposed by the copyright holder.
Additional terms will be linked to the Project Gutenberg™
License for all works posted with the permission of the copyright
holder found at the beginning of this work.

1.E.4. Do not unlink or detach or remove the full Project

Gutenberg™ License terms from this work, or any files
containing a part of this work or any other work associated with
Project Gutenberg™.
1.E.5. Do not copy, display, perform, distribute or redistribute
this electronic work, or any part of this electronic work, without
prominently displaying the sentence set forth in paragraph 1.E.1
with active links or immediate access to the full terms of the
Project Gutenberg™ License.

1.E.6. You may convert to and distribute this work in any binary,
compressed, marked up, nonproprietary or proprietary form,
including any word processing or hypertext form. However, if
you provide access to or distribute copies of a Project
Gutenberg™ work in a format other than “Plain Vanilla ASCII” or
other format used in the official version posted on the official
Project Gutenberg™ website (www.gutenberg.org), you must, at
no additional cost, fee or expense to the user, provide a copy, a
means of exporting a copy, or a means of obtaining a copy upon
request, of the work in its original “Plain Vanilla ASCII” or other
form. Any alternate format must include the full Project
Gutenberg™ License as specified in paragraph 1.E.1.

1.E.7. Do not charge a fee for access to, viewing, displaying,

performing, copying or distributing any Project Gutenberg™
works unless you comply with paragraph 1.E.8 or 1.E.9.

1.E.8. You may charge a reasonable fee for copies of or

providing access to or distributing Project Gutenberg™
electronic works provided that:

• You pay a royalty fee of 20% of the gross profits you derive
from the use of Project Gutenberg™ works calculated using
the method you already use to calculate your applicable
taxes. The fee is owed to the owner of the Project
Gutenberg™ trademark, but he has agreed to donate
royalties under this paragraph to the Project Gutenberg
Literary Archive Foundation. Royalty payments must be paid
within 60 days following each date on which you prepare (or
are legally required to prepare) your periodic tax returns.
Royalty payments should be clearly marked as such and
sent to the Project Gutenberg Literary Archive Foundation at
 the address specified in Section 4, “Information about
donations to the Project Gutenberg Literary Archive
Foundation.”

• You provide a full refund of any money paid by a user who

notifies you in writing (or by e-mail) within 30 days of receipt
that s/he does not agree to the terms of the full Project
Gutenberg™ License. You must require such a user to return
or destroy all copies of the works possessed in a physical
medium and discontinue all use of and all access to other
copies of Project Gutenberg™ works.

• You provide, in accordance with paragraph 1.F.3, a full

refund of any money paid for a work or a replacement copy,
if a defect in the electronic work is discovered and reported
to you within 90 days of receipt of the work.

• You comply with all other terms of this agreement for free
distribution of Project Gutenberg™ works.

1.E.9. If you wish to charge a fee or distribute a Project

Gutenberg™ electronic work or group of works on different
terms than are set forth in this agreement, you must obtain
permission in writing from the Project Gutenberg Literary
Archive Foundation, the manager of the Project Gutenberg™
trademark. Contact the Foundation as set forth in Section 3
below.

1.F.

1.F.1. Project Gutenberg volunteers and employees expend

considerable effort to identify, do copyright research on,
transcribe and proofread works not protected by U.S. copyright
law in creating the Project Gutenberg™ collection. Despite
these efforts, Project Gutenberg™ electronic works, and the
medium on which they may be stored, may contain “Defects,”
such as, but not limited to, incomplete, inaccurate or corrupt
data, transcription errors, a copyright or other intellectual
property infringement, a defective or damaged disk or other
medium, a computer virus, or computer codes that damage or
cannot be read by your equipment.

1.F.2. LIMITED WARRANTY, DISCLAIMER OF DAMAGES -

Except for the “Right of Replacement or Refund” described in
paragraph 1.F.3, the Project Gutenberg Literary Archive
Foundation, the owner of the Project Gutenberg™ trademark,
and any other party distributing a Project Gutenberg™ electronic
work under this agreement, disclaim all liability to you for
damages, costs and expenses, including legal fees. YOU
AGREE THAT YOU HAVE NO REMEDIES FOR NEGLIGENCE,
STRICT LIABILITY, BREACH OF WARRANTY OR BREACH
OF CONTRACT EXCEPT THOSE PROVIDED IN PARAGRAPH
1.F.3. YOU AGREE THAT THE FOUNDATION, THE
TRADEMARK OWNER, AND ANY DISTRIBUTOR UNDER
THIS AGREEMENT WILL NOT BE LIABLE TO YOU FOR
ACTUAL, DIRECT, INDIRECT, CONSEQUENTIAL, PUNITIVE
OR INCIDENTAL DAMAGES EVEN IF YOU GIVE NOTICE OF
THE POSSIBILITY OF SUCH DAMAGE.

1.F.3. LIMITED RIGHT OF REPLACEMENT OR REFUND - If

you discover a defect in this electronic work within 90 days of
receiving it, you can receive a refund of the money (if any) you
paid for it by sending a written explanation to the person you
received the work from. If you received the work on a physical
medium, you must return the medium with your written
explanation. The person or entity that provided you with the
defective work may elect to provide a replacement copy in lieu
of a refund. If you received the work electronically, the person or
entity providing it to you may choose to give you a second
opportunity to receive the work electronically in lieu of a refund.
If the second copy is also defective, you may demand a refund
in writing without further opportunities to fix the problem.

1.F.4. Except for the limited right of replacement or refund set

forth in paragraph 1.F.3, this work is provided to you ‘AS-IS’,
WITH NO OTHER WARRANTIES OF ANY KIND, EXPRESS
OR IMPLIED, INCLUDING BUT NOT LIMITED TO
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR
ANY PURPOSE.

1.F.5. Some states do not allow disclaimers of certain implied

warranties or the exclusion or limitation of certain types of
damages. If any disclaimer or limitation set forth in this
agreement violates the law of the state applicable to this
agreement, the agreement shall be interpreted to make the
maximum disclaimer or limitation permitted by the applicable
state law. The invalidity or unenforceability of any provision of
this agreement shall not void the remaining provisions.

1.F.6. INDEMNITY - You agree to indemnify and hold the

Foundation, the trademark owner, any agent or employee of the
Foundation, anyone providing copies of Project Gutenberg™
electronic works in accordance with this agreement, and any
volunteers associated with the production, promotion and
distribution of Project Gutenberg™ electronic works, harmless
from all liability, costs and expenses, including legal fees, that
arise directly or indirectly from any of the following which you do
or cause to occur: (a) distribution of this or any Project
Gutenberg™ work, (b) alteration, modification, or additions or
deletions to any Project Gutenberg™ work, and (c) any Defect
you cause.

Section 2. Information about the Mission of

Project Gutenberg™
Project Gutenberg™ is synonymous with the free distribution of
electronic works in formats readable by the widest variety of
computers including obsolete, old, middle-aged and new
computers. It exists because of the efforts of hundreds of
volunteers and donations from people in all walks of life.
Volunteers and financial support to provide volunteers with the
assistance they need are critical to reaching Project
Gutenberg™’s goals and ensuring that the Project Gutenberg™
collection will remain freely available for generations to come. In
2001, the Project Gutenberg Literary Archive Foundation was
created to provide a secure and permanent future for Project
Gutenberg™ and future generations. To learn more about the
Project Gutenberg Literary Archive Foundation and how your
efforts and donations can help, see Sections 3 and 4 and the
Foundation information page at www.gutenberg.org.

Section 3. Information about the Project

Gutenberg Literary Archive Foundation
The Project Gutenberg Literary Archive Foundation is a non-
profit 501(c)(3) educational corporation organized under the
laws of the state of Mississippi and granted tax exempt status by
the Internal Revenue Service. The Foundation’s EIN or federal
tax identification number is 64-6221541. Contributions to the
Project Gutenberg Literary Archive Foundation are tax
deductible to the full extent permitted by U.S. federal laws and
your state’s laws.

The Foundation’s business office is located at 809 North 1500

West, Salt Lake City, UT 84116, (801) 596-1887. Email contact
links and up to date contact information can be found at the
Foundation’s website and official page at
www.gutenberg.org/contact

Section 4. Information about Donations to

the Project Gutenberg Literary Archive
Foundation
Project Gutenberg™ depends upon and cannot survive without
widespread public support and donations to carry out its mission
of increasing the number of public domain and licensed works
that can be freely distributed in machine-readable form
accessible by the widest array of equipment including outdated
equipment. Many small donations ($1 to $5,000) are particularly
important to maintaining tax exempt status with the IRS.

The Foundation is committed to complying with the laws

regulating charities and charitable donations in all 50 states of
the United States. Compliance requirements are not uniform
and it takes a considerable effort, much paperwork and many
fees to meet and keep up with these requirements. We do not
solicit donations in locations where we have not received written
confirmation of compliance. To SEND DONATIONS or
determine the status of compliance for any particular state visit
www.gutenberg.org/donate.

While we cannot and do not solicit contributions from states

where we have not met the solicitation requirements, we know
of no prohibition against accepting unsolicited donations from
donors in such states who approach us with offers to donate.

International donations are gratefully accepted, but we cannot

make any statements concerning tax treatment of donations
received from outside the United States. U.S. laws alone swamp
our small staff.

Please check the Project Gutenberg web pages for current

donation methods and addresses. Donations are accepted in a
number of other ways including checks, online payments and
credit card donations. To donate, please visit:
www.gutenberg.org/donate.

Section 5. General Information About Project

Gutenberg™ electronic works
Professor Michael S. Hart was the originator of the Project
Gutenberg™ concept of a library of electronic works that could
be freely shared with anyone. For forty years, he produced and
distributed Project Gutenberg™ eBooks with only a loose
network of volunteer support.

Project Gutenberg™ eBooks are often created from several

printed editions, all of which are confirmed as not protected by
copyright in the U.S. unless a copyright notice is included. Thus,
we do not necessarily keep eBooks in compliance with any
particular paper edition.

Most people start at our website which has the main PG search
facility: www.gutenberg.org.

This website includes information about Project Gutenberg™,

including how to make donations to the Project Gutenberg
Literary Archive Foundation, how to help produce our new
eBooks, and how to subscribe to our email newsletter to hear
about new eBooks.